Wave Life Sciences, Inc. — Form 8-K
Filed November 18, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Wave Life Sciences, Inc. amended and restated its 2021 Equity Incentive Plan effective November 12, 2026, to reflect the company's redomiciliation from Singapore to Delaware on August 7, 2026. The plan authorizes 41,950,000 common shares for awards (options, restricted stock, SARs, performance awards) to employees, consultants, and directors, plus any forfeited shares from the prior 2014 plan. No specific new awards, dollar amounts, or share grants were disclosed in this filing—it documents the plan's assumption by the Delaware entity post-redomiciliation.
Why this rating
Redomiciliation is administrative/structural; plan amendment is routine post-M&A cleanup. No new equity issuance, material grant, or business change disclosed. Boilerplate equity plan governance at ~$851M company.
See more from November 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.